17b malcolm skingle, gsk, session 4

Page 1

“Good Practice Models for International University-Industry Collaboration” Malcolm Skingle CBE DSc PhD Director – Academic Liaison Drug Discovery Wednesday 11th January 2012 Building University – Business links symposium British Embassy & British Council meeting


Opening Remarks • Companies must collaborate to innovate & survive • Companies can no longer fund all of the research they require to underpin their R&D operations • No single university has all of the answers ! • Governments compete for inward investment • GSK support collaborative research in almost 30 countries • Leveraging research funding is essential for companies


The Structural Genomics Consortium - an open access public-private partnership


The Structural Genomics Consortium an Open Access Public Private Partnership Board of Directors Wayne Hendrickson, Columbia, Chair

Scientific Committee Kirk Clark, Chair, Novartis

CEO Aled Edwards

SGC-Oxford

SGC-Toronto

SGC-Stockholm

~65 staff

~80 staff

~25 staff


The Structural Genomics Consortium - an open access public-private partnership Mandate to place protein structures of relevance to human health into the public domain, free from restrictions on use.

• Funders nominate the SGC Target List of proteins • •

Phase 1: (2005-07) 455 protein structures solved

Phase 2: (2007-11) Target of 660 structures from the Target List (2400 proteins) plus 8 human integral membrane proteins


Target distribution among SGC Laboratories

SGC-Oxford

SGC-Toronto

SGC-Stockholm

–Dehydrogenases, Reductases & Metabolism –Phosphorylation Dependent Signaling –Transmembrane Receptor Signaling –Diabetes and signalling –Chromatin –Apicomplexan-associated diseases –GTPases, ATPases and small molecule kinases – Nucleotide metabolism and RNA helicases – Amino acid metabolism – Lipid signalling

Shared best practice: Methodology & technology


Protein Kinases (Catalytic Domains) Human kinases (518 in genome)

Kinase Structures in Public Databases

20 15 10 5 0 19 93 19 94 19 95 19 96 19 97 19 98 19 99 20 00 20 01 20 02 20 03 20 04 20 05 20 06

Unique Kinase Structures

25

Year of first release in pdb


Thirteen SGC Funders •

The Wellcome Trust.

• • • • •

The Canada Foundation for Innovation (CFI), The Canadian Institutes of Health Research (CIHR), Genome Canada, The Ontario Genomics Institute (OGI), The Ontario Ministry of Research and Innovation (MRI),

GlaxoSmithKline plc. (GSK), Merck & Co., Inc., Novartis, Pfizer

• • • •

Karolinska Institutet, The Knut and Alice Wallenberg Foundation, The Swedish Foundation for Strategic Research, VINNOVA (The Swedish Governmental Agency for Innovation Systems),

>£50m 4 year programme


Developing Chemical Probes for Epigenetics No structures disclosed

Structures disclosed

Chemistry @ GSK X-ray @ Oxford Public Domain

Assays @ Oxford Chemical Probe

* Sigma make probe available

Data to GSK

Only GSK scientists can view data with compound structures

1–5 Compounds meeting probe criteria for potency and selectivity:

* e.g. Potency <100nM, Selectivity >100, Cellular activity <1uM


A future model for Drug Discovery? Wellcome Trust Epigenetics Collaboration GSK-WT-SGC Partnership

Public Domain

Chemical Tractability

Chemical Probes

Drug Discovery

Chemistry (GSK) Screening (WT-NIH) Structure (SGC)

No restrictions on use or publication

Proprietary Target Validation (Re)Screening Lead optimization Pharmacology DMPK Toxicology Chemical development Clinical development

Enable Academic Target Validation

Open Access

Pharmaceutical Industry

Proprietary


Q: Why place Chemical Probes in the Public Domain? A: Potent and selective small molecules provide complimentary (if not better) target validation to genetic methods as evidenced by their scientific impact Compound

Receptor

Papers

Citations

Years

h-index

g-index

GW1929

PPARγ

317

11063

14

47

100

GW0742

PPARδ

392

7212

10

41

78

GW4064

FXR

250

4482

8

37

61

SR12813

PXR

127

4628

8

33

67

GW9662

PPARγ

528

4513

8

32

50

GW3965

LXR

181

3073

7

29

53

GW7647

PPARα

118

2312

7

22

47

CITCO

CAR

73

711

5

14

24

Data compiled from Google Scholar, October 5, 2007

All compounds were made available by GSK to the Public Domain through commercial suppliers (Sigma-Aldrich and Tocris) h-index: a metric of scientific impact, combining quality and quantity of citations g index: a modification of the h-index with more weight on highly-cited articles


Innovation through Public Private Partnerships • Address large research challenges • Access to ……….. Complementary skills and/or technologies Academic lateral thinking Multi-disciplinary problem solving Co-funding

• •

Critical mass In order to work well……. Confidence & trust between partner(s) Shared risks & rewards


We are looking for innovation wherever it may originate


Turn static files into dynamic content formats.

Create a flipbook
Issuu converts static files into: digital portfolios, online yearbooks, online catalogs, digital photo albums and more. Sign up and create your flipbook.